- Home
- ELDN vs LRMR Comparison
ELDN vs LRMR Comparison
Compare ELDN & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- LRMR
- Stock Information
- Founded
- ELDN 2004
- LRMR N/A
- Country
- ELDN United States
- LRMR United States
- Employees
- ELDN N/A
- LRMR N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- ELDN Health Care
- LRMR Health Care
- Exchange
- ELDN Nasdaq
- LRMR Nasdaq
- Market Cap
- ELDN 178.4M
- LRMR 183.8M
- IPO Year
- ELDN N/A
- LRMR N/A
- Fundamental
- Price
- ELDN $3.06
- LRMR $2.18
- Analyst Decision
- ELDN Strong Buy
- LRMR Strong Buy
- Analyst Count
- ELDN 1
- LRMR 8
- Target Price
- ELDN $16.00
- LRMR $19.63
- AVG Volume (30 Days)
- ELDN 214.2K
- LRMR 1.3M
- Earning Date
- ELDN 05-14-2025
- LRMR 04-30-2025
- Dividend Yield
- ELDN N/A
- LRMR N/A
- EPS Growth
- ELDN N/A
- LRMR N/A
- EPS
- ELDN N/A
- LRMR N/A
- Revenue
- ELDN N/A
- LRMR N/A
- Revenue This Year
- ELDN N/A
- LRMR N/A
- Revenue Next Year
- ELDN N/A
- LRMR N/A
- P/E Ratio
- ELDN N/A
- LRMR N/A
- Revenue Growth
- ELDN N/A
- LRMR N/A
- 52 Week Low
- ELDN $2.30
- LRMR $1.61
- 52 Week High
- ELDN $5.54
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- ELDN 49.05
- LRMR 54.85
- Support Level
- ELDN $2.96
- LRMR $1.80
- Resistance Level
- ELDN $3.27
- LRMR $2.33
- Average True Range (ATR)
- ELDN 0.17
- LRMR 0.18
- MACD
- ELDN 0.02
- LRMR 0.04
- Stochastic Oscillator
- ELDN 53.33
- LRMR 90.00
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.